MedCity News August 11, 2022
Katie Cheng and William Jackson

Concerns about who qualifies under the 340B Program, how drugs can be dispensed to patients, and how much entities will be reimbursed may significantly impact the operation of the 340B Program as Congress intended. This evolving landscape poses challenges to all stakeholders.

On June 15, 2022, the Supreme Court issued an opinion in favor of 340B hospitals rejecting steep reductions in reimbursements for covered 340B drugs that the Centers for Medicare and Medicaid Services (“CMS”) had tried to implement in 2018. But even following this decision, all entities involved in the 340B Drug Pricing Program (“340B Program”) still face a significant amount of uncertainty in complying with its requirements. In addition to the reimbursement amount issue, the U.S. Department of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Health System / Hospital, HHS, Patient / Consumer, Pharma, Pharma / Biotech, Provider
Nation's 1st double lung-liver transplant performed at Northwestern
Physician Compensation Continues To Decline, Despite A Dire Shortage
340B profit exceeds charity care spending for 85% of disproportionate share hospitals: Report
Ascension continues selling spree
Healthcare security culture steadily improving, but gaps remain

Share This Article